HORAN Wealth LLC Sells 8,965 Shares of Bristol Myers Squibb Company $BMY

HORAN Wealth LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY) by 48.6% in the second quarter, HoldingsChannel.com reports. The firm owned 9,491 shares of the biopharmaceutical company’s stock after selling 8,965 shares during the period. HORAN Wealth LLC’s holdings in Bristol Myers Squibb were worth $547,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Davis Asset Management L.P. bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at $27,000. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Addison Advisors LLC bought a new stake in Bristol Myers Squibb in the second quarter valued at about $32,000. Finally, Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.0%

Shares of NYSE BMY opened at $66.85 on Tuesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The firm’s 50-day simple moving average is $63.09 and its 200 day simple moving average is $59.96. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a market cap of $136.56 billion, a price-to-earnings ratio of 14.72, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the previous year, the firm posted $1.46 earnings per share. The company’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. TD Cowen initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating for the company. Sanford C. Bernstein raised Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Bank of America cut their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Raymond James Financial started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Finally, Citigroup reiterated a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Insider Buying and Selling

In other news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.